E Fund Management Co., Ltd. I Mab Transaction History

E Fund Management Co., Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$3.22 - $4.86 $126,207 - $190,487	-39,195 Reduced 38.37%	62,962 $263,000
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $1.24 Million - $3.83 Million	-310,000 Reduced 75.21%	102,157 $410,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $187,447 - $417,734	-22,666 Reduced 5.21%	412,157 $4.66 Million
Q1 2022 May 12, 2022	BUY	$12.54 - $46.93 $577,467 - $2.16 Million	46,050 Added 11.84%	434,823 $7.01 Million
Q4 2021 Feb 11, 2022	BUY	$45.28 - $74.5 $2.04 Million - $3.36 Million	45,126 Added 13.13%	388,773 $18.4 Million
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $698,625 - $1.03 Million	-12,218 Reduced 3.43%	343,647 $24.9 Million
Q1 2021 May 12, 2021	BUY	$44.38 - $63.97 $15.8 Million - $22.8 Million	355,865 New	355,865 $17.2 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.